Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: YES.

Abstract

Despite the development of highly efficient and more targeted immunotherapies for multiple sclerosis (MS), two major unmet needs still exist: (1) the need for treatment to suppress compartmentalized and meningeal inflammation in the central nervous system (CNS), which seems to drive the progression of disability1 and is less responsive to the majority of immunomodulatory drugs, and (2) the need for a treatment that may substantially promote regeneration-remyelination.